Full Article at IIR has reaffirmed its Recommended rating for PIA after undertaking a review post the appointment of a new Portfolio Manager, Harding Loevner. The full report can be found on the IIR website. On 26 July 2021, Pengana International Equities Limited (PIA) announced a fully franked dividend of 1.35 cents per share for the June quarter. This represents an 8% increase on the March quarter dividend and takes the total dividends declared for FY21 of 5.1 cents per share, fully franked....
CAMBRIDGE, England--(BUSINESS WIRE)-- Abzena, plc (AIM: ABZA, Abzena’), the life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products, has signed an antibody humanisation agreement with Tmunity Therapeutics (Tmunity), a clinical stage T cell therapy company and a leader in the development of new Chimeric Antigen Receptor T Cell (CAR-T) therapies for the treatment of solid and hematological cancers. Under the agreement Abzena will humanize monoclonal antibod...
CAMBRIDGE, England--(BUSINESS WIRE)-- Abzena plc (AIM: ABZA, ‘Abzena’), the life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products, has entered into a master service agreement with one of America’s leading academic medical centres, NYU Langone Health (New York, US). The agreement, for protein engineering and drug discovery services, will help NYU Langone’s drug discovery accelerator, the Office of Therapeutics Alliances (OTA), to develop novel biopharmaceutical t...
Following a stronger H2 and Abzena’s FY18 results, we have made major changes to our model across both the services business and the Abzena Inside royalty portfolio. The FY18 reported revenues of £22.0m were ahead of our forecast and up c 18% over FY17. This was driven by 60% growth in bio-manufacturing where fortunately, most of the investment in capacity was directed in FY18. Last week’s announcement of a proposed royalty monetisation will help to address the FY19 working capital requirem...
CAMBRIDGE, England & BRISTOL, Pa.--(BUSINESS WIRE)-- Abzena plc, the life sciences group providing services and technologies to enable the design, development and manufacture of biopharmaceutical products, has announced the completion of the facility remodelling for its new antibody-drug conjugate (ADC) GMP manufacturing suite at its Bristol, Pennsylvania site. The facility is being equipped with state-of-the-art Sartorius and GE equipment for single use scale-up, manufacture and purification processes. The environmentally co...
CAMBRIDGE, England--(BUSINESS WIRE)-- Abzena plc, the life sciences group providing services and technologies to enable the discovery, design, development and manufacture of biopharmaceutical products, has signed an agreement to access a major cell line depository. The agreement with an unnamed institution will allow Abzena access to cell lines representing multiple different species, tissue types and genetic disorders. This removes the lengthy process of negotiating individual cell line licences for Abzena and its customers....
In its interim results for the year-ending March 2018, Abzena started to move out from under the shadow of September’s disappointing trading update. Investors should be relieved that Abzena continues to demonstrate a growing service business even against the backdrop of an investment programme aimed at increasing capacity. Group revenues were up 7.6% year-on-year for the first half, while the Abzena Inside portfolio continues to expand and products within it advance.
CAMBRIDGE, England & SINGAPORE--(BUSINESS WIRE)-- Abzena plc (AIM: ABZA, ‘Abzena’), the life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products, works with Enleofen Bio Pte Ltd (‘Enleofen Bio'), to develop first-in-class antibody therapeutics for the treatment of fibrotic human diseases. The Founders of Enleofen Bio discovered that inhibiting Interleukin 11 (IL11) prevents fibrosis through a wide range of pathways, putting it at the very centre of the fib...
In the November edition of the Hardman Monthly Newsletter, Nigel Hawkins assesses the achievements of AIM – and how it has thrived, despite a challenging financial environment, in recent years. ► AIM, which was founded in 1995, now hosts 959 stocks, currently worth over £100 billion. ► Since its founding, over £100 billion has been raised by AIM-quoted stocks – with 2006 and 2007 being its best years. ► The AIM Index has risen by 31% over the last year and by over 60% during the las...
CAMBRIDGE, England & HENNIGSDORF, Germany--(BUSINESS WIRE)-- Abzena plc (AIM: ABZA, 'Abzena' or the 'Group'), the life sciences group providing integrated solutions and technologies enabling the development and manufacture of biopharmaceutical products, and UGA Biopharma GmbH, a cell line development specialist, announce the completion of the development of a biosimilar cell line to treat Multiple Sclerosis (MS). The partnership centred around the development of an NS0 (murine myeloma) manufacturing cell line, expressing a high qual...
Abzena is a global life sciences group offering a broad range of integrated services and technologies to enable the development of better biopharmaceutical drugs. With strong footprints in both the US and UK, the company provides a fee-for-service offering with the opportunity of embedding its technology – ‘Abzena Inside’ – into commercial products, with potential to derive a long-term royalty stream. Following a period of integration, a capital increase was undertaken in April 2017 for ...
Abzena announced a disappointing business update, indicating revenues for each of its service lines have been below expectations. This has an impact on H118 revenues, which the company now expects to be broadly in line with H117. Abzena has, however, indicated that there is good order cover and high engagement for new business and therefore expects H2 to be significantly stronger. We have reduced our forecasts and valuation to £110m (vs £160m) or 52p/share (vs 75p) following a review. A solid up...
Abzena has announced another licensing deal, this time involving its Composite Human Antibody technology. The deal is with Telix Pharmaceuticals, a biopharmaceutical company which specialises in the development and commercialisation of radiopharmaceuticals. The agreement is the third announced this year, which includes royalties and milestone payments, based on successful development, alongside a service contract. We have reviewed our service business valuation as we expect these deals to enable...
CAMBRIDGE, England & MELBOURNE, Australia--(BUSINESS WIRE)-- Abzena plc (AIM: ABZA, ‘Abzena’), the life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products, has signed a licence agreement with Telix Pharmaceuticals Limited (‘Telix’), a biopharmaceutical company specializing in the development and commercialisation of radiopharmaceuticals for diagnostic (imaging) and therapeutic use (the “Agreement”). Under the terms of the Agreement, Abzena has granted Tel...
Abzena has announced another licensing deal for its proprietary site-specific ThioBridge antibody drug conjugate (ADC) linker technology. This time it is with a Taiwanese biopharmaceutical company (OBI Pharma). The agreement enables the development of OBI Pharma’s proprietary ADC, OBI-999. The deal also allows OBI to develop further ADCs as potential treatments for cancer and includes a master services and clinical supply agreement. This again provides important validation of Abzena’s ADC techno...
CAMBRIDGE, England & TAIPEI, Taiwan--(BUSINESS WIRE)-- Abzena plc (AIM: ABZA, ‘Abzena’ or the ‘Group’), the life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products, has signed a licensing agreement and a master services and clinical supply agreement with OBI Pharma, a Taiwanese biopharmaceutical company (‘OBI’, TPEx: 4174). The licensing agreement is for Abzena’s novel site-specific ThioBridge™ antibody drug conjugate (ADC) linker technology to develop OBI’s ...
Abzena reported solid FY17 results with underlying revenue growth of 41% (to £18.7m). In FY17, Abzena continued to focus on the integration of its service offering across its three sites (US and UK), which has been expanded by its recent placing of £25m gross (issuing 75.8m new shares at 33p). We expect this to enable strong growth and take Abzena to profitability in FY20, which will be a significant milestone for the company. We maintain our valuation at £132m, 62p per share, but note potential...
CAMBRIDGE, England--(BUSINESS WIRE)-- Abzena plc (AIM: ABZA, ‘Abzena’ or the ‘Group’), a life sciences group providing services and technologies enabling the development and manufacture of biopharmaceutical products, has published its full year results for the year to 31 March 2017. Corporate highlights Integration of Abzena’s service offering for biopharmaceutical development and manufacturing across three sites in UK and US delivering expected revenue synergies Licence deal with U...
Abzena recently announced a placing of £25m gross (issuing 75.8m new shares at 33p) to expand its service offering, capacity and capabilities. Importantly, we expect this fund-raising to take Abzena to profitability, which will be a significant milestone for the company. We have increased our valuation to £132m (vs £105m), primarily due to the increase in forecast service revenues, improved gross margin and cash position.
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.